Surgery for malignant pleural mesothelioma

Expert Review of Respiratory Medicine

Volumn 4, Issue 3, 2010, Pages 363-372

  Sugarbaker, David J ^a   Wolf, Andrea S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Extrapleural pneumonectomy; Median survival; Pleurectomy decortication; Resectability; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CRS 207; GEMCITABINE; MORAB 009; NAVELBINE; PEMETREXED; RAPAMYCIN; SS 1P; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DECORTICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EMPYEMA; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INFECTIOUS COMPLICATION; INTENSITY MODULATED RADIATION THERAPY; LUNG DISEASE; LUNG RESECTION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PLEURA MESOTHELIOMA; PLEURECTOMY; PREOPERATIVE EVALUATION; PROGNOSIS; REVIEW; SURGICAL MORTALITY; SURGICAL TECHNIQUE; THORACOTOMY; THROMBOSIS;

EID: 77953279289     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.35     Document Type: Review

References (70)

1. Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J. Thorac. Oncol. 1(2), 175-176 (2006).
2. Sarot IA. Extrapleural pulmonary resection and pleurectomy (pleuro-pneumonectomy) for tuberculosis and empyema. Trans. Annu. Meet. Natl Tuberc. Assoc. 46, 253-254 (1950).
3. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 31(1), 15-24 (1976).
4. Sugarbaker DJ, Jaklitsch MT, Bueno R et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J. Thorac. Cardiovasc. Surg. 128(1), 138-146 (2004).
5. Yan TD, Boyer M, Tin MM et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J. Thorac. Cardiovasc. Surg. 138(3), 619-624 (2009).
6. Rusch VW, Rosenzweig K, Venkatraman E et al. A Phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 122(4), 788-795 (2001).
7. Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 18(7), 1196-1202 (2007).
8. de Perrot M, Feld R, Cho BC et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27(9), 1413-1418 (2009).
9. Krug LM, Pass HI, Rusch VW et al. Multicenter Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27(18), 3007-3013 (2009).
10. Flores RM, Pass HI, Seshan VE et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J. Thorac. Cardiovasc. Surg. 135(3), 620-626 (2008).
11. Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann. Thorac. Surg. 85(2), 424-429 (2008).
12. Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 125(3), 250-256 (1999).
13. Veillette G, Dominguez I, Ferrone C et al. Implications and management of pancreatic fistulas following pancreaticoduodenectomy: the Massachusetts General Hospital experience. Arch. Surg. 143(5), 476-481 (2008).
14. Virani S, Michaelson JS, Hutter MM et al. Morbidity and mortality after liver resection: results of the patient safety in surgery study. J. Am. Coll. Surg. 204(6), 1284-1292 (2007).
15. Ambrogi V, Mineo D, Gatti A, Pompeo E, Mineo TC. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J. Surg. Oncol. 100(3), 199-204 (2009).
16. Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 103(4 Suppl.), 382S-384S (1993).
17. Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin. Thorac. Cardiovasc. Surg. 21(2), 132-148 (2009).
18. Soysal O, Karaoglanoglu N, Demiracan S et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur. J. Cardiothorac. Surg. 11(2), 210-213 (1997).
19. Baldini EH, Recht A, Strauss GM et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 63(2), 334-338 (1997).
20. Flores RM. Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/ decortication. Semin. Thorac. Cardiovasc. Surg. 21(2), 149-153 (2009).
21. Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117(1), 54-63 (1999).
22. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg. 68(5), 1799 - 1804 (1999).
23. Maggi G, Casadio C, Cianci R, Rena O, Ruffini E. Trimodality management of malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 19(3), 346-350 (2001).
24. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur. J. Cardiothorac. Surg. 22(2), 298-305 (2002). (Pubitemid 34831874)
25. Flores RM, Krug LM, Rosenzweig KE et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J. Thorac. Oncol. 1(4), 289-295 (2006).
26. Schipper PH, Nichols FC, Thomse KM et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann. Thorac. Surg. 85(1), 257-264; discussion 64 (2008).
27. Pass HI, Temeck BK, Kranda K et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann. Surg. Oncol. 4(8), 628-633 (1997).
28. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 115(2), 310-317; discussion 317-318 (1998).
29. Moskal TL, Urschel JD, Anderson TM, Antkowiak JG, Takita H. Malignant pleural mesothelioma: a problematic review. Surg. Oncol. 7(1-2), 5-12 (1998).
30. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
31. Merritt N, Blewett CJ, Miller JD, Bennett WF, Young JE, Urschel JD. Survival after conservative (palliative) management of pleural malignant mesothelioma. J. Surg. Oncol. 78(3), 171-174 (2001).
32. Calavrezis A, Koschel G, Husselmann H et al. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. Klin. Wochenschr. 66, 607-613 (1988).
33. Kutcher GJ, Kestler C, Greenblatt D, Brenner H, Hilaris BS, Nori D. Technique for external beam treatment for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 13(11), 1747-1752 (1987).
34. Yajnik S, Rosenzweig KE, Mychalczak B et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 56(5), 1319-1326 (2003).
35. Ahamad A, Stevens CW, Smythe WR et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 55(3), 768-775 (2003).
36. Forster KM, Smythe WR, Starkschall G et al. Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int. J. Radiat. Oncol. Biol. Phys. 55(3), 606-616 (2003).
37. Rice DC, Stevens CW, Correa AM et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 84(5), 1685-1692; discussion 1692-1693 (2007).
38. Allen AM, Czerminska M, Janne PA et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 65(3), 640-645 (2006).
39. Miles EF, Larrier NA, Kelsey CR et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int. J. Radiat. Oncol. Biol. Phys. 71(4), 1143-1150 (2008).
40. Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21(2), 159-163 (2009).
41. Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21(2), 177-187 (2009).
42. Friedberg JS, Mick R, Stevenson J et al. A Phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann. Thorac. Surg. 75(3), 952-959 (2003).
43. Friedberg JS, Mick R, Stevenson JP et al. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J. Clin. Oncol. 22(11), 2192-2201 (2004).
44. Tilleman TR, Richards WG, Zellos L et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a Phase II prospective study. J. Thorac. Cardiovasc. Surg. 138(2), 405-411 (2009).
45. Richards WG, Zellos L, Bueno R et al. Phase I to II study of pleurectomy/ decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J. Clin. Oncol. 24(10), 1561-1567 (2006).
46. Zellos L, Richards WG, Capalbo L et al. A Phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 137(2), 453-458 (2009).
47. Jackman D. Current options for systemic therapy in mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21, 154-158 (2009).
48. Hartman M, Esposito J, Yeap B, Sugarbaker D. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J. Thorac. Cardiovasc. Surg. 139(5), 1233-1240 (2010).
49. Vogelzang NJ. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 50(Suppl. 1), S23-S24 (2005).
50. Castagneto B, Zai S, Dongiovanni D et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a Phase II study. Am. J. Clin. Oncol. 28(3), 223-226 (2005).
51. Kalmadi SR, Rankin C, Kraut MJ et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a Phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60(2), 259-263 (2008).
52. van Haarst JM, Baas P, Manegold C et al. Multicentre Phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br. J. Cancer 86(3), 342-345 (2002). (Pubitemid 34187648)
53. Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3), 308-313 (2009).
54. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br. J. Cancer 99(1), 44-50 (2008).
55. Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 22(17), 3451-3457 (2004).
56. Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 9(4), 347-355 (1997).
57. Corson JM. Pathology of mesothelioma. Thorac. Surg. Clin. 14(4), 447-460 (2004).
58. Corson JM, Pinkus GS. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am. J. Pathol. 108(1), 80-88 (1982).
59. Travis WD, Colby TV, Corrin B, Brambilla E. World Health Organization International Histological Classification of Tumours: Histological Typing of Lung and Pleural Tumours (3rd Edition). Travis WD (Ed.). Springer, Berlin, Germany (1999).
60. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108(4), 1122-1128 (1995).
61. Richards WG, Godleski JJ, Yeap BY et al. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 116(6), 1510-1517 (2010).
62. Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21(2), 97-104 (2009).
63. Gill R, Gerbaudo V, Sugarbaker D, Hatabu H. Current trends in radiologic management of malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21, 111-120 (2009).
64. Mujoomdar A, Matsuoka S, Hatabu H et al. Reduced lung volume measured by CT predicts unresectability in mesothelioma patients. Presented at: 9th Biennial Conference of the International Mesothelioma Interest Group, 2008. Amsterdam, The Netherlands, 24-26 September 2008.
65. Gordon GJ, Dong L, Yeap BY et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J. Natl Cancer Inst. 101(9), 678-686 (2009).
66. Bueno R. Making the case for molecular staging of malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21(2), 188-193 (2009).
67. Mujoomdar A, Tilleman T, Richards W, Bueno R, Sugarbaker D. Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens. J. Thorac. Cardiovasc. Surg. (2009) (In Press).
68. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44(1), 46-53 (2008).
69. Figure 103.2. In: Adult Chest Surgery (First Edition). The McGraw-Hill Companies, NY, USA (2009).
70. Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin. Thorac Cardiovasc. Surg. 21(2), 132-148 (2009).